Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.680
+0.080 (5.00%)
At close: Nov 26, 2025, 4:00 PM EST
1.740
+0.060 (3.57%)
After-hours: Nov 26, 2025, 7:59 PM EST
Outlook Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Outlook Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.25, which forecasts a 212.50% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $9.00.
Price Target: $5.25 (+212.50%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1 | Hold | Reiterates | $1 | -40.48% | Sep 30, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $8 | Strong Buy | Maintains | $21 → $8 | +376.19% | Sep 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $1 | Strong Buy → Hold | Downgrades | $1 | -40.48% | Aug 29, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +78.57% | Aug 28, 2025 |
Financial Forecast
Revenue This Year
6.86M
Revenue Next Year
30.38M
from 6.86M
Increased by 342.80%
EPS This Year
-1.68
from -4.06
EPS Next Year
-0.99
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 13.2M | 63.9M | ||||
| Avg | 6.9M | 30.4M | ||||
| Low | 4.1M | 15.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 831.8% | ||||
| Avg | - | 342.8% | ||||
| Low | - | 127.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.56 | -0.29 | ||||
| Avg | -1.68 | -0.99 | ||||
| Low | -1.78 | -1.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.